Ana Moreno received a B.S. in biosystems engineering with a focus on biosensors and a B.A. in French literature from the University of Arizona. She went on to earn an M.S. and Ph.D. in bioengineering from the University of California, San Diego, where her research focused on developing epigenetic gene therapy platforms using CRISPR-dCas9 and zinc-finger technologies. Ana has authored multiple high-impact research papers, holds six patents and received numerous prestigious awards and fellowships, including the CONACYT and UC MEXUS Graduate Fellowships, the Engelson Ph.D. Thesis Award, the Mitchell Max Award from the NIH Pain Consortium, and the 2024 Biocom California Catalyst Award.
In 2018, Ana founded Navega Therapeutics, a company dedicated to transforming patients’ lives through AI-enabled epigenetic therapies, with a focus on treating intractable pain and inflammatory disorders. She is also deeply passionate about mentoring and promoting diversity in STEM and has served as a mentor at San Diego Squared (SD2), the Basement at UC San Diego and Scientella.